Hidroxizina Pentafarma

Hidroxizina Pentafarma is a prescription medication that contains hydroxyzine hydrochloride, a first‑generation H1‑receptor antagonist, supplied in oral dosage form. Marketed in the European Union, it is classified as an antihistamine with anxiolytic and sedative properties. The product is intended for use under medical supervision for allergic skin conditions, itching, anxiety relief, and procedural sedation, and should be taken only as directed by a healthcare professional.

Hidroxizina Pentafarma is prescribed for several clinical situations where its antihistamine and central nervous system effects are beneficial.

- Relief of itching associated with allergic dermatoses such as urticaria or eczema. - Management of generalized anxiety or tension in adults. - Short‑term sedation before or after minor surgical or diagnostic procedures. - Adjunctive treatment of nausea or vomiting related to anxiety or medication side effects. - Control of pruritus in chronic liver disease or renal failure.

Adverse reactions to Hidroxizina Pentafarma are generally related to its antihistaminic and anticholinergic activity.

Common: - Drowsiness or sedation - Dry mouth - Blurred vision - Constipation - Headache - Dizziness

Serious: - Severe allergic reaction (anaphylaxis) - Cardiac arrhythmias or QT interval prolongation - Seizures - Hepatic dysfunction - Acute angle‑closure glaucoma

When prescribing Hidroxizina Pentafarma, clinicians should consider several safety factors.

- Do not use in patients with known hypersensitivity to hydroxyzine or related compounds. - Use caution in the elderly, who may be more susceptible to sedation and anticholinergic effects. - Avoid operating machinery or driving until the individual’s response to the drug is known. - Adjust dosing in patients with hepatic or renal impairment, as clearance may be reduced. - Pregnancy and lactation safety have not been established; use only if the potential benefit justifies the risk. - Concomitant use with alcohol or other central nervous system depressants may enhance sedation. - Monitor patients with glaucoma, urinary retention, or prostatic hypertrophy for worsening symptoms.

Hydroxyzine can interact with several medication classes, requiring attention to avoid adverse outcomes.

Avoid: - Other central nervous system depressants (e.g., benzodiazepines, opioids, alcohol). - Additional antihistamines or anticholinergic agents, which may increase anticholinergic burden. - Monoamine oxidase inhibitors (MAOIs) due to the risk of heightened serotonergic effects. - Drugs known to prolong the QT interval, increasing the risk of cardiac arrhythmias. - Strong CYP3A4 inhibitors that could raise hydroxyzine plasma concentrations.

Use with caution: - CYP3A4 inducers (e.g., rifampin) that may reduce hydroxyzine effectiveness. - Certain antidepressants (e.g., tricyclics) that share anticholinergic properties. - Antihypertensive agents, as hydroxyzine may cause additive hypotensive effects. - Diabetic medications, because sedation could mask hypoglycemia symptoms. - Other medications metabolized by the liver, requiring monitoring for altered drug levels.